{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:26:59Z","timestamp":1781224019556,"version":"3.54.1"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Real\u2010world evidence comparing clinical outcomes between venetoclax and Bruton tyrosine kinase inhibitors (BTKis) in patients with frontline (1\u2009L) chronic lymphocytic leukaemia (CLL) is lacking. We compared treatment effectiveness of 1\u2009L venetoclax plus obinutuzumab (VenO) versus BTKi\u2010based regimens. This retrospective observational study using Optum Clinformatics Data Mart\u00ae included adult patients with CLL (\u22652 outpatient or \u22651 inpatient claim) who received VenO or BTKi\u2010based regimens in 1\u2009L (1\/2019\u20139\/2022). Baseline characteristics were balanced using stabilised inverse probability weighting. Outcomes included duration of therapy (DoT), persistence, time to next treatment or death (TTNT\u2010D), and time off\u2010treatment. Among 1506 eligible patients (VenO: 203; BTKi: 1303), the median follow\u2010up duration was 12.6 (VenO) and 16.2\u2009months (BTKi). Median DoT for VenO was 12.3\u2009months; persistence remained higher in VenO versus BTKi through expected 1\u2009L fixed treatment duration. Median TTNT\u2010D was not reached for VenO; however, more VenO\u2010 versus BTKi\u2010treated patients had not switched therapies\/experienced death through Month 12 (87.1% vs. 75.3%). Among patients that discontinued, median time to discontinuation was 11.7 vs. 5.9\u2009months for VenO versus BTKi and median time off\u2010treatment was 11.3 vs. 4.3\u2009months. In this real\u2010world study, VenO was associated with better effectiveness outcomes than BTKi\u2010based regimens in 1\u2009L CLL.<\/jats:p>","DOI":"10.1111\/bjh.19613","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:15:50Z","timestamp":1721866550000},"page":"1395-1403","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real\u2010world comparative effectiveness of venetoclax\u2010obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia"],"prefix":"10.1111","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[{"name":"Atrium Health Levine Cancer Institute  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0329-3465","authenticated-orcid":false,"given":"Beenish S.","family":"Manzoor","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7243","authenticated-orcid":false,"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[{"name":"Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnadozie","family":"Emechebe","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Alhasani","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Skarbnik","sequence":"additional","affiliation":[{"name":"Novant Health Cancer Institute  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dureshahwar","family":"Jawaid","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.10.105"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0715-5"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00258"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00645-1"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000412"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S177009"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060463"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.10.012"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00756-9"},{"key":"e_1_2_11_17_1","unstructured":"AgencyEM.Venetoclax SmPC.2018[cited 2023 Oct 2]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/venclyxto\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_18_1","unstructured":"ClinicalTrials.gov.Ibrutinib monotherapy versus fixed\u2010duration venetoclax plus obinutuzumab versus fixed\u2010duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukaemia (CLL) (CLL17). [Cited 2023 Oct 2]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04608318"},{"key":"e_1_2_11_19_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Lymphocytic Leukemia\/ Small Lymphocytic Lymphoma Version 2.\u00a9 National Comprehensive Cancer Network Inc. 2024. All rights reserved. Accessed [March 11 2024]. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"e_1_2_11_21_1","unstructured":"BiniekJF DamicoA CubanskiJ NeumanT.Medicare beneficiaries rarely change their coverage during open enrollment.2022[Cited 2023 Oct 2]. Available from:https:\/\/www.kff.org\/medicare\/issue\u2010brief\/medicare\u2010beneficiaries\u2010rarely\u2010change\u2010their\u2010coverage\u2010during\u2010open\u2010enrollment\/"},{"key":"e_1_2_11_22_1","unstructured":"OchiengN CubanskiJ FreedM NeumanT.A relatively small share of medicare beneficiaries compared plans during a recent open enrollment period.2022[Cited 2023 Oct 2]. Available from:https:\/\/www.kff.org\/medicare\/issue\u2010brief\/a\u2010relatively\u2010small\u2010share\u2010of\u2010medicare\u2010beneficiaries\u2010compared\u2010plans\u2010during\u2010a\u2010recent\u2010open\u2010enrollment\u2010period\/"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00919-1"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.25270\/jcp.2022.06.1"},{"key":"e_1_2_11_25_1","first-page":"2222","article-title":"PB2353: healthcare resource utilization and costs off therapy with fixed\u2010duration venetoclax among CLL patients","volume":"6","author":"Allan JN","year":"2022","journal-title":"Hema"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.174"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.09.007"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.010"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100930"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016953"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051504"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143648"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:33:39Z","timestamp":1758098019000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/bjh.19613"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19613","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"2024-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}